Citi raised the firm’s price target on Neurocrine (NBIX) to $203 from $175 and keeps a Buy rating on the shares following the Q3 beat. The firm says Crenessity significantly outperformed expectations in Q3 and is positioned to be a blockbuster.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Neurocrine Biosciences Reports Strong Q3 2025 Growth
- Neurocrine’s Strong Q3 Performance and Growth Potential Justify Buy Rating
- Neurocrine’s Strong Performance and Strategic Initiatives Drive Buy Rating
- Neurocrine reports Q3 adjusted EPS $2.17, consensus $2.07